Move Over Turing, Valeant – Mylan Next Target For Price Scrutiny
Executive Summary
So far, most of the attention on drug price increases has focused on Turing Pharmaceuticals AG and Valeant Pharmaceuticals International Inc. But Mylan NV soon could be in the bull's-eye of payers and lawmakers after hiking the prices of 24 of the firm's products by more than 20% in the past six month, with seven of those medicines' costs spiking more than 100%, Wells Fargo analyst David Maris said in a new report.
You may also be interested in...
Mylan Could Get Out Of EpiPen Price Backlash With A Little Contrition, Analyst Says
Mylan CEO Heather Bresch may have done her company little favors by arguing it couldn't reduce EpiPen's price, with one analyst telling the firm it needs to get a little contrition and acknowledge its decision to raise the medicine's cost.
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Mylan's $600 price tag for its emergency anaphylaxis treatment EpiPen (epinephrine) could spur more than probes into the company's pricing practices. It could turn into a wider investigation into industry's use of patient assistance programs.
Life's A Musical For Martin Shkreli
The absurdity that's surrounded former drug company CEO Martin Shkreli, who has been indicted on eight federal charges, including securities fraud, has been made into a New York musical – really!